Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gene Therapy Guidances From US FDA Coming In About 6 Weeks, Gottlieb Says

Executive Summary

Potential accelerated approval endpoints will be addressed; FDA Commissioner expects gene therapy to become a 'backbone' treatment as antibodies are now.

You may also be interested in...



Gene Therapy Oversight To Be Streamlined By US FDA, NIH

Streamlining adverse event reports among reform ideas; NIH's Recombinant DNA Advisory Committee likely to drop review of more routine protocols.

Gene Therapies Need Long-Term Follow-Up Plan From Outset Or Risk Clinical Hold

Although a sponsor may conclude that a long-term follow-up protocol is not necessary for a gene therapy, FDA may have a different interpretation, and the agency won't let studies start if that's the case, draft gudiance states.

Gene Therapy 'Cassettes' Could Speed, Cheapen Manufacturing, Gottlieb Says

US FDA Commissioner teases endpoints, suggests accelerated approval plan and post-marketing considerations for gene therapies targeting hemophilia.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS123086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel